8-K: Neurocrine Biosciences Announces $300 Million Accelerated Share Repurchase Program

Neurocrine Biosciences has entered into an accelerated share repurchase agreement with Goldman Sachs to buy back $300 million of its common stock.

Summary

• Neurocrine Biosciences has initiated an accelerated share repurchase (ASR) program to buy back $300 million of its common stock.
• The ASR agreement is with Goldman Sachs & Co. LLC.
• Neurocrine will pay the $300 million repurchase price on November 4, 2024.
• Initially, Neurocrine will receive shares equal to 80% of the repurchase price, based on the closing share price on October 31, 2024.
• The final number of shares repurchased will be determined by the volume-weighted average price during the ASR term, less a discount.
• The ASR transaction is scheduled to conclude in the first quarter of 2025.
• Depending on the final settlement, Neurocrine may receive additional shares or may need to deliver shares or make a cash payment to Goldman Sachs.

Sentiment

Score: 7

Explanation: The announcement of a share repurchase program is generally viewed positively by investors, indicating management's confidence in the company's future prospects. However, the potential for adjustments and the final settlement terms introduce some uncertainty.

Positives

• The share repurchase program signals management's confidence in the company's value.
• The ASR program allows for a quicker buyback of shares compared to open market purchases.
• The repurchase may increase earnings per share and potentially boost the stock price.

Risks

• The final number of shares repurchased and the ultimate cost to the company are subject to market fluctuations.
• There is a possibility that Neurocrine may need to deliver additional shares or make a cash payment to Goldman Sachs at the final settlement.
• The ASR transaction could be accelerated, extended, or terminated early by Goldman Sachs under certain conditions.

Future Outlook

The ASR transaction is scheduled to terminate in the first quarter of 2025, at which point the final number of shares repurchased will be determined.

Industry Context

Share repurchase programs are a common way for companies to return capital to shareholders, especially when they believe their stock is undervalued. This move by Neurocrine is consistent with this trend.

Comparison to Industry Standards

• Many large pharmaceutical and biotech companies use share repurchase programs to manage their capital structure and enhance shareholder value.
• Accelerated share repurchase programs are often used to quickly execute large buybacks, similar to programs used by companies such as Amgen and Gilead Sciences.
• The 80% initial share delivery is a common structure in ASR agreements, aligning with industry practices.

Stakeholder Impact

• Shareholders may benefit from the share repurchase program through increased earnings per share and potential stock price appreciation.
• The company's financial position may be impacted by the cash outflow for the repurchase.

Next Steps

• Neurocrine will pay the repurchase price on November 4, 2024.
• The ASR transaction will continue until the first quarter of 2025.
• The final settlement of the ASR transaction will determine the total number of shares repurchased and any potential cash or share adjustments.

Key Dates

Keywords

share repurchase, accelerated share repurchase, ASR, Neurocrine Biosciences, Goldman Sachs, stock buyback, capital allocation